We Were on a Break!

Most U.S. states and jurisdictions are experiencing substantial or high levels of community transmission fueled by the spread of the highly contagious B.1.617.2 (Delta) variant. COVID-19 cases, hospitalizations, and deaths continue to increase, especially in communities with lower vaccination coverage. While the number of people getting vaccinated also continues to increase, many people remain unsure about getting vaccinated, and others do not plan to do so.

On July 27, 2021, CDC announced updated Guidance for COVID-19 Prevention Strategies based on emerging evidence of the B.1.617.2 (Delta) variant. CDC recommends that all people, regardless of vaccination status, wear masks in public indoor settings in areas of substantial or high transmission. A new CDC study supports previous findings that B.1.617.2 (Delta) is highly contagious, and is contributing to an increase in cases, including those with severe outcomes and those due to vaccine breakthrough infections. While vaccinated people can still develop COVID-19, they are far less likely to get severely sick or die than people who are unvaccinated.

United States Levels of Community Transmission

Vaccination is the best tool we have for protecting ourselves and our loved ones against COVID-19. The COVID-19 vaccines authorized for use in the United States continue to protect against severe illness, hospitalizations, and death. To find a vaccine provider near you, visit Vaccines.gov or your state or local public health department website. If you or someone you know is hesitant about COVID-19 vaccination, CDC has information and answers to frequently asked questions to help make informed decisions.

Link to PDF of this Document

Link to CDC Website




Aug. 6, 2021 – Golisano Children’s Hospital’s Mobile Pediatric Vaccination Clinic will be making stops around Southwest Florida next week to vaccinate children 12 years-old and older for COVID-19.

The Mobile Pediatric Vaccination Clinic is walk-up only, and there is no cost for the COVID-19 vaccine, which will be Pfizer. 

The mobile clinic will be at the following locations next week:

  • Monday, August 9, 9 a.m.-12:30 p.m., Salvation Army’s Homeless Resource Day Center, 2450 Edison Ave., Fort Myers
  • Monday, August 9, 3-6 p.m., Immokalee Community Park, 321 N 1st St., Immokalee

A parent or authorized guardian must accompany a minor for vaccination. The second dose will be set for the same location or one nearby.

Anyone 12 years old and older can also receive their COVID-19 vaccine at no cost at Lee Health’s Community Vaccination Clinic, located at Gulf Coast Medical Center. For more information, visit www.leehealth.org.

About Lee Health

Since the opening of the first hospital in 1916, Lee Health has been a health care leader in Southwest Florida, constantly evolving to meet the needs of the community. A non-profit, integrated health care services organization, Lee Health is committed to the well-being of every individual served, focused on healthy living and maintaining good health. Staffed by caring people, inspiring health, services are conveniently located throughout the community in four acute care hospitals, two specialty hospitals, outpatient centers, walk-in medical centers, primary care and specialty physician practices and other services across the continuum of care. Learn more at www.LeeHealth.org




Miami, FL – The Florida Department of Health in Miami-Dade County (DOH-Miami-Dade) is offering additional appointments this Saturday, August 7, for the Pfizer-BioNTech and Johnson & Johnson’s Jannsen COVID-19 vaccine. The Pfizer BioNTech vaccine is available to individuals 12 years of age and older while the Johnson & Johnson’s Jannsen vaccine is available to individuals 18 years of age and older. The vaccines will be offered by appointment at the following location:

Health District Center – DOH-Miami-Dade site 1350 NW 14 Street, Miami Florida 33125

To schedule an appointment, follow the attached link on google chrome
https://public.domo.com/cards/v2mAg

All individuals under the age of 18 receiving a vaccine must be accompanied by a parent or guardian and must complete the COVID-19 vaccine screening and consent form.

As per State Surgeon General Dr. Scott Rivkees’ Public Health Advisory issued on April 29, 2021, vaccine access and eligibility is expanded to any individual in Florida who is present in Florida for the purpose of providing goods or services for the benefit of residents and visitors of the state.

About the Florida Department of Health
The department works to protect, promote and improve the health of all people in Florida through integrated state, county and community efforts.
Follow us on Twitter at @HealthyFla and on Facebook. For more information about the Florida Department of Health please visit www.FloridaHealth.gov.




August 3, 2021–Three years after the National Institutes of Health (NIH) launched its 10-year All of Us Research Program, a regional team led by University of Miami Miller School of Medicine faculty has achieved remarkable success in recruiting members of minority communities including Black and Latino participants.

Despite the challenges of the COVID-19 pandemic, more than 24,000 volunteers from the Southeast region have enrolled in the national landmark program, including a high percentage of minorities who are under-represented in medical research. Now, the program has reopened for the enrollment of new participants.

“Traditional medical research has been based on people with European ancestry,” said Henri R. Ford, M.D., M.H.A., dean and chief academic officer of the Miller School. “It’s time we changed that. For personalized care to become a reality, all our communities need to be represented in medical research. I’m proud that the Miller School and UHealth – the University of Miami Health System are partners in this initiative.”

All of Us is the most extensive and most inclusive research program undertaken by the National Institutes of Health. By asking one million or more volunteers across the nation to share different types of health and lifestyle information, the initiative aims to speed up health research breakthroughs to improve health outcomes and deliver precision and personalized medicine to patients.

With its expertise in genetics and genomics and its location in one of the most ethnically diverse counties in the nation, the Miller School is the lead partner in the study’s SouthEast Enrollment Center (SEEC), which includes the University of Florida, and Emory University and Morehouse College of Medicine in Georgia. There are nine other academic consortia across the nation, as well a the Veterans Administration and several Community Health Centers that are also enrolling participants that reflect the geographic, ethnic, racial, socioeconomic, age, and gender diversity of the U.S.

“The All of Us Research Program, an NIH flagship initiative, has selected the University of Miami as one of its 10 national lead sites – one of the largest grants the Miller School has ever received,” said Stephan Züchner, M.D., Ph.D., professor and the SEEC’s lead principal investigator (PI), who chairs UM’s Dr. John T. Macdonald Foundation Department of Human Genetics and co-directs the John P. Hussman Institute for Human Genomics. “This is allowing us to truly make a contribution to the inclusion of ALL Americans into research studies, regardless of race, income, zip code, etc. Only such a diverse national research program at an unprecedented scale has the scientific power to unlock personalized medicine for rare and common ailments, well-being, aging, and more. Consequently, the benefits of this research will ultimately benefit ‘all of us’.”

Ongoing enrollment success

The Southeast region has enrolled more than 24,000 participants in Florida and Georgia, including 11,000 from Miami-Dade, said Olveen Carrasquillo, M.D., M.P.H., professor of public health sciences, chief of the Division of General Internal Medicine, and an All of Us PI who serves as the SEEC’s participant engagement lead. “More than 70 percent of our participants have diverse minority backgrounds, and in Miami-Dade, that percentage is even higher — about 85.5 percent,” he added.

During the pandemic, All of Us enrollment was paused as program staffers were engaged in vaccine trials. “Now, more than ever, the COVID-19 pandemic has highlighted the need and urgency of health research,” said Dr. Carrasquillo. “All of Us is creating a significant resource for researchers to be able to understand the patterns of COVID-19 and get a fuller picture of how it spread in the U.S. Some groups of people are being hit harder than others. It’s important to find out why.”

Noting that the All of Us regional team includes more than 110 faculty and staff, Dr. Züchner said, “This is an outstanding team effort. It takes time to build a collaborative research program that can recruit thousands of participants. This is a marathon, not a sprint.”

First-time access to genetic data

As part of the All of Us Research Program, NIH recently released a Researcher Workbench with tools and health data to drive new biomedical discoveries. For the first time, researchers have access to information about All of Us participants’ experience with the COVID-19 pandemic through answers to survey questions on mental health, social distancing, and economic impacts.

“The opening of the Researcher Workbench allows scientists, physicians, and qualified students and trainees from the University of Miami to access more than 280,000 biomedical datasets, soon complete with genomic data,” said Dr. Zuchner.

Currently, 75% of participants whose data is in the Researcher Workbench come from communities that are historically underrepresented in research, such as people of color (about 50%) and sexual and gender minorities, according to NIH. The workbench encompasses various data types, including survey responses, physical measurements, electronic health records (EHRs), and wearable fitness data.

A new baseline

Along with genetic information, the All of Us research program is collecting vital data about individual lifestyles and environments that can affect how individual genes are expressed and impact overall health outcomes. “This is one of the most exciting aspects of the research program,” Dr. Carrasquillo said. “Studying DNA is a key part of this effort, and participants will be contributing to many future studies to improve the health of everyone.”

Rosario Isasi, J.D., M.P.H., research associate professor of human genetics, added that obtaining gene samples from participants will help identify causes of disease and potential new therapies. “There is also the issue of justice,” said Isasi, a lawyer/bioethicist and a principal investigator supporting ethics/regulatory aspects of the research program and co-chair of the All of Us Committee on Access Privacy and Security (CAPS). “We all contribute to biomedical research through our taxes, and we all are all a part of humanity. The hope is to address the shortcomings of the past and support meaningful discoveries for everyone within a robust ethical framework.”

Benefits of enrolling

Jacob L. McCauley, Ph.D., associate professor of human genetics and pathology, and director of the Hussman Institute’s Center for Genome Technology, agreed with the importance of keeping All of Us participants engaged in the ongoing research program.

“We are really excited that participants have started receiving some of their genetic results from the biosamples that they have donated,” said McCauley, a principal investigator who is leading logistics and other SEEC efforts and serves on the Biospecimen Access Policy Task Force. “The initial results will provide insights into the participants’ genetic ancestry and traits, with additional health-related results coming at a later phase. This is one of the first opportunities to return value to our participant partners in this groundbreaking research program.”

Dr. McCauley added one of the benefits of participating is that participants can get their DNA results over time. “When we process your DNA, we will be able to check your DNA for information of interest to each individual,” he said. “Some examples include ancestry, traits, or certain health-related DNA results that you can then discuss with your health care provider.”

Lessons for the future

The success of the All of Us recruitment campaign may also provide valuable lessons for future clinical trials, according to Dr. McCauley. “We hope to leverage our team’s outreach efforts,” he said. “For instance, much of our success has been our ability to build face-to-face relationships, explaining our research program, answering questions, and gaining participant trust.”

Looking ahead, Dr. Ford said he looks forward to the findings from the 10-year research program, which will help clinicians create individual prevention, treatment, and care plans for patients of all races and ethnic groups. “This vital initiative will improve healthcare for generations to come,” he said. “I invite you to participate in the All of Us research program because we are one U!”

To enroll

The All of Us team at the University of Miami is now accepting new participants – just call 305-243-8380 to book an appointment. “We have implemented procedures to ensure everyone feels safe,” said Dr. Carrasquillo. “That includes a COVID-19 Symptom Checker prior to arriving, complete sanitation of clinic space after each participant, and reengineering spaces to allow for physical distancing and prevent overcrowding. A reminder that no visitors are currently allowed on campus.”

All participants will receive $25 cash after completion of their visit. To complete the visit, participants must create an account at JoinAllofUs.org and fill out the necessary enrollment and consent forms. The online process, which takes about 30 minutes, includes watching informational videos and answering several health surveys. While online, participants will need to give their consent, agree to share their electronic health records, decide whether they want information about their DNA, and agree to have their physical measurements taken (height, weight, blood pressure, etc.), and give blood and urine samples.

Participants who complete those steps will be invited later to a University of Miami site to provide their physical measurements, including height, weight and blood pressure, and blood and urine samples. The data, which will be encrypted and subject to robust privacy safeguards, will be used to build the national All of Us database. The program will contact participants about new surveys and additional ways to share information over time.

The SouthEast Enrollment Center is supported under NIH funding award #1OT2OD025285. “All of Us” is a registered service mark of the U.S. Department of Health and Human Services.




Bradenton resident joins the National Alzheimer’s Association Early-Stage Advisory Group

August 5, 2021 – The Alzheimer’s Association has selected Bradenton resident Deborah (“Deb”) Jobe to serve on its 2021-2022 Alzheimer’s Association National Early-Stage Advisory Group (ESAG). Jobe is one of 10 individuals chosen to serve on the group, which helps raise awareness of Alzheimer’s and other dementia by sharing their personal insights and experiences of living with dementia with media and other audiences across the country.

More than 6 million Americans are currently living with Alzheimer’s disease, including 580,000 in Florida. ESAG members play an important role in giving voice to those living with the disease and advocate for core Alzheimer’s Association efforts, including increasing concern and awareness of the disease, enhancing care and support programs for individuals and families, advancing public policy initiatives and championing support for disease research.

“Early-stage advisors play a vital role in Alzheimer’s Association advocacy efforts,” said Michelle Branham, Alzheimer’s Association Florida region vice president of public policy. “They bring a unique perspective that not only informs our work, but also inspires others living with the disease to engage in efforts that can make a difference for all those affected.”

Chosen from more than 50 applicants across the country, Jobe was diagnosed with posterior cortical atrophy and mild cognitive impairment in 2019 at the age of 53. At the time, she had been experiencing memory issues for a couple of years, but the diagnosis, she said, still hit her hard.

“It was utter devastation,” she recalled. “It was as if your world was suddenly turned upside down and you are floundering, attempting to grasp and process what it means for the future and what to do next.”

Following her diagnosis, Jobe’s medical team acted immediately, providing her with care and support resources, including referring her to the Alzheimer’s Association, where she found support among others going through similar circumstances.

Now, Jobe uses her voice to advocate for others. Recently, she was also appointed as a patient voice to the National Institute of Health (NIH) Geriatric Emergency Care Applied Research Network 2.0 – Advancing Dementia Care (GEAR 2.0 ADC) to improve the experience and care in emergency departments for people with dementia.

“The Alzheimer’s Association was my saving grace,” Jobe said. “Getting involved and sharing my story in an effort to help others has given me a newfound purpose, and it’s improved my quality of life.”

Formed in 2006, the national ESAG group and its advisors have helped to secure the addition of younger-onset Alzheimer’s to the Social Security Administration’s Compassionate Allowance Initiative, giving those with the disease access to certain social security benefits. They also participated in grassroots advocacy efforts supporting the establishment of the first national plan to address the Alzheimer’s epidemic. ESAG members also advocate for increased research funding and provide input to the Association about programs and materials designed to meet the growing needs of early-stage individuals.

As a member of the 2021-2022 National Early Stage Advisory Group, Jobe said she hopes to help change the public’s perception of what living with dementia is like and educate people on the benefits of early detection and diagnosis.

“Prior to my diagnosis, I thought Alzheimer’s and other dementia only impacted old people,” she said. “Now, I realize there are many different faces and stages of the disease. But the one thing we all have in common is that we are human and deserve to be treated with respect. I intend to use my voice for as long as I can to help educate people about dementia and the challenges it brings.”

About the Alzheimer’s Association

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia – by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia™. Visit alz.org or call 800.272.3900. ​